Atlas Trials

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

Clinical trial NCT04398147 · UNKNOWN

Trial details

NCT number
NCT04398147
Sponsor
CanSino Biologics Inc.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2020-08-01
Primary completion
2021-12-20
Enrollment
696

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.